Iomab-B & Phase 3 SIERRA Trial Highlights

A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML

John Pagel, M.D., Ph.D. discussing Iomab-B for HSCT (bone marrow transplant) in Older Patients with Relapsed/Refractory Acute Myeloid Leukemia

Joseph Jurcic, M.D. discussing Iomab-B in Refractory AML: can older patients with active disease be transplanted?

Highlights: Key Opinion Leader Event on Bone Marrow Transplant, Potential Role of Iomab-B

Highlights Segment from discussion on bone marrow transplantation and radioimmunotherapy; Phase III Drug Candidate: Iomab-B

Key Opinion Leader Event on Bone Marrow Transplant, Potential Role of Iomab-B

Discussion on bone marrow transplantation and radioimmunotherapy; Phase III Drug Candidate: Iomab-B

Highlights: New York BIO-CONference Panel on Iomab-B

Highlights Segment from Physicians Panel Discussion on the Future of AML Treatment for Elderly Relapsed/Refractory Patients

Iomab-B’s impact on the treatment of AML

Leaders in the field of AML treatment discuss the impact of Iomab-B

New York BIO-CONference Panel on Iomab-B

Can Older Refractory/Relapsed AML Patients Undergo Successful BMT without Entering CR First?

The Potential of Iomab-B to Revolutionize and Expand Bone Marrow Transplant

Live from ASH 2011: Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzu

Promise of Alpha Therapy

Dr. Kantarjian of Actinium's Clinical Advisory Board Discusses AML Treatment

Emerging Opportunities in Targeted Payload Cancer Therapeutics